[Clinical approval of dalargin--a new agent for treating peptic ulcer].
D000293:Adolescent; D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002927:Cimetidine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004743:Enkephalin, Leucine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016308:Enkephalin, Leucine-2-Alanine / Q000031:analogs & derivatives*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000188:drug therapy*; D012008:Recurrence
D000897:Anti-Ulcer Agents; D004743:Enkephalin, Leucine; D016308:Enkephalin, Leucine-2-Alanine; D002927:Cimetidine; C040996:enkephalin-Leu, Ala(2)-Arg(6)-
Klinicheskaia aprobatsiia dalargina--novogo sredstva dlia lecheniia iazvennoĭ bolezni.